As illustrated in Figure 3(C,D), Rho-TRAIL-Cou-NPs exhibited more drug accumulation at the tumor sites compared to Cou-NPs, suggesting that TRAIL endowed the nanoparticles with active tumor-targeting ability. This evidence concerns the gene TNFSF10 and neoplasm.